Clinical trial Recruiting at 1 site Interventional Ages 19 to 70

Sugammadex-Induced Mouth Clenching After Reversing Neuromuscular Blockade

Official title: A Prospective, Randomized, Double-Blind Study of the Incidence, Severity, and Risk Factors of Clenching Induced by Sugammadex During Neuromuscular Blockade Reversal

Run by Wonkwang University Hospital · NCT06962007 · Data updated 2026-11-12

This trial tests whether different doses of sugammadex or a pyridostigmine/glycopyrrolate combo affect mouth clenching after reversing a muscle block in adults undergoing surgery.

More General Anesthesia trials

Quick facts

Study typeInterventional
Ages19 Years to 70 Years
SexAll
Enrollment240 (estimated)
SponsorWonkwang University Hospital
Academic / other
Locations1 site (Iksan, Jeonbuk-do)
StatusRecruiting
StartedJuly 1, 2025
Main results expectedSeptember 20, 2026
Study endsOctober 14, 2026
Registry record updatedJuly 7, 2026
Trial IDNCT06962007 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 19-70 years old, ASA I-II, undergoing elective surgery with rocuronium who consent to participate.

Probably not a fit

Patients with neuromuscular disorders, severe renal impairment, known dental issues or clenching history, or those undergoing emergency surgery may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, randomized, double-blind study enrolling adults 19 to 70 years old with ASA I-II status undergoing elective surgery with rocuronium-induced neuromuscular blockade. Participants are assigned to receive sugammadex at 1, 2, or 4 mg/kg, or a pyridostigmine/glycopyrrolate combination, to see how often and how severely jaw clenching occurs within 10 minutes of reversal. Clenching is measured by clinical observation, masseter EMG, and airway pressure changes, using a five-level severity scale. Secondary outcomes include timing to TOF ratio recovery, BIS values at clenching onset, airway complications, and identification of risk factors. The study aims to clarify safety signals related to airway management and patient comfort during emergence from anesthesia.

Why it matters

Potential benefit: If successful, the findings could help optimize dosing strategies to minimize jaw clenching and improve emergence from anesthesia.

How similar studies have gone: Previous reports have documented sugammadex-related jaw clenching, but randomized, dose-ranging data with standardized severity scoring are limited, making this investigation comparatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Eligible participants are adults aged 19-70 years, American Society of Anesthesiologists (ASA) physical status I-II, undergoing elective surgery under general anesthesia with rocuronium.

Exclusion Criteria:

* Exclusion criteria include neuromuscular disorders, renal impairment (creatinine clearance \< 30 mL/min), history of clenching or dental disease, allergy to study drugs, or emergency surgery.

Where it's running

  • Wonkwang University hospital
    Iksan, Jeonbuk-do, South Korea
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.